ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1772

Venous Thromboembolic Events in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Chiara Baldini1, Francesco Ferro1, Nicoletta Luciano1, Antonio Tavoni2, Francesca Sernissi1, Daniela Martini1, Sara L'Abbate1, Marta Mosca3 and Stefano Bombardieri3, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2University of Pisa, Immunoallergology Unit, Pisa, Italy, 3Rheumatology Unit, University of Pisa, Pisa, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Churg-Strauss syndrome and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous studies have documented an increased risk of venous thromboembolic events in patients with antineutrophil cytoplasmic antibodies (ANCA) associated vasculitides (AAV) as compared to healthy subjects. However, only a limited number of studies have analyzed the prevalence of thrombosis in eosinophilic granulomatosis with polyangiitis (EGPA).Aim of the study was to determine the frequency of venous thromboembolic events (VTE) in a single center cohort of patients with EGPA and to describe its relation with disease clinical manifestations and activity.

Methods: Patients diagnosed with EGPA (1990 ACR classification criteria) from 1994 to 2014 were included in the study. Data were retrospectively retrieved from patients’ charts, including gender, demographic data, cumulative clinical features, ANCA status and BVAS at the baseline. In patients with VTE (i.e deep venous thrombosis and/or pulmonary embolism), EGPA  characteristics and disease activity at the time of VTE occurrence were also collected. Categorical variables were compared using Fisher’s exact test; continuous variables were compared using Student’s t-test. A 2-tailed value of p < 0.05 was taken to indicate statistical significance. 

Results: The systematic search of our database identified 89 patients, among whom 51 were included in the study. Median (IQR) age at the EGPA diagnosis was 59 (41-62.2) years and their M:F sex ratio was 1.04. During a median (IQR) follow-up of 72.2 (14.8-135.2) months, 6/51 (11.8%) EGPA patients presented at least one VTE. One patient presented 4 recurrent thromboses despite anticoagulant therapy; overall, then, 9 VTE were recorded. Lower-limb deep venous thromboses (DVTs) were the most common VTE manifestations, representing the 89% (8/9) of all the VTE in our series. One patients developed also a pulmonary embolism, while another presented a cardiac intra-ventricular thrombus. Six (67%) VTE occurred within 6 months before the EGPA diagnosis. The patient with recurrent thromboses presented 2 DVTs before the EGPA diagnosis and 2 further DVTs within 15 months after the EGPA diagnosis. The patient with the pulmonary embolism, developed the VTE 13 years after EGPA diagnosis concomitantly with a femoral neck fracture. According to our analysis, factors associated with the occurrence of VTE were renal involvement (p=0.01), nephrotic range proteinuria >3 g/24 h (p = 0.03) and a FFS>1 (p=0.03). No differences were observed regarding theANCA status and the BVAS score at the diagnosis between the groups.

Conclusion: The results of this study confirm a higher risk of VTE in patients with EGPA. The pathogenesis of thrombosis in EGPA calls for further studies.


Disclosure:

C. Baldini,
None;

F. Ferro,
None;

N. Luciano,
None;

A. Tavoni,
None;

F. Sernissi,
None;

D. Martini,
None;

S. L’Abbate,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/venous-thromboembolic-events-in-eosinophilic-granulomatosis-with-polyangiitis-egpa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology